Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer

被引:55
作者
Gordon-Weeks, A. N. [1 ]
Lim, S. Y. [1 ]
Yuzhalin, A. E. [1 ]
Jones, K. [1 ]
Muschel, R. [1 ]
机构
[1] Univ Oxford, CRUK MRC Gray Inst Radiat Oncol & Biol, Oxford OX1 2JD, England
关键词
Colon cancer; Inflammation; MIF; Macrophage migration inhibitory factor; SODIUM-INDUCED COLITIS; PHENYLPYRUVATE TAUTOMERASE ACTIVITY; INFLAMMATORY-BOWEL-DISEASE; CHEMOKINE RECEPTOR CXCR4; HUMAN COLORECTAL-CANCER; FACTOR MIF TAUTOMERASE; ULCERATIVE-COLITIS; CRYSTAL-STRUCTURE; MURINE MODEL; SEVERE SEPSIS;
D O I
10.1016/j.cytogfr.2015.03.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Macrophage migration inhibitory factor (MIF) was one of the first cytokines to be discovered, over 40 years ago. Since that time a burgeoning interest has developed in the role that MIF plays in both the regulation of normal physiology and the response to pathology. MIF is a pleotropic cytokine that functions to promote inflammation, drive cellular proliferation, inhibit apoptosis and regulate the migration and activation state of immune cells. These functions are particularly relevant for the development of cancer and it is notable that various solid tumours over express MIF. This includes tumours of the gastrointestinal tract and MIF appears to play a particularly prominent role in the development and progression of colonic adenocarcinoma. Here we review the role that MIF plays in colonic carcinogenesis through the promotion of colonic inflammation, as well as the progression of primary and metastatic colon cancer. The recent development of various antagonists and antibodies that inhibit MIF activity indicates that we may soon be able to classify MIF as a therapeutic target in colon cancer patients. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:451 / 461
页数:11
相关论文
共 138 条
[1]   ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis [J].
Al-Abed, Y ;
Dabideen, D ;
Aljabari, B ;
Valster, A ;
Messmer, D ;
Ochani, M ;
Tanovic, M ;
Ochani, K ;
Bacher, M ;
Nicoletti, F ;
Metz, C ;
Pavlov, VA ;
Miller, EJ ;
Tracey, KJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (44) :36541-36544
[2]   MIF as a disease target: ISO-I as a proof-of-concept therapeutic [J].
Al-Abed, Yousef ;
VanPatten, Sonya .
FUTURE MEDICINAL CHEMISTRY, 2011, 3 (01) :45-63
[3]   Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials [J].
Algra, Annemijn M. ;
Rothwell, Peter M. .
LANCET ONCOLOGY, 2012, 13 (05) :518-527
[4]   Blockade of macrophage migration inhibitory factor (MIF) prevents the antigen-induced response in a murine model of allergic airway inflammation [J].
Amano, T. ;
Nishihira, J. ;
Miki, I. .
INFLAMMATION RESEARCH, 2007, 56 (01) :24-31
[5]   Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB [J].
Amin, MA ;
Haas, CS ;
Zhu, K ;
Mansfield, PJ ;
Kim, MJ ;
Lackowski, NP ;
Koch, AE .
BLOOD, 2006, 107 (06) :2252-2261
[6]   Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase [J].
Amin, MA ;
Volpert, OV ;
Woods, JM ;
Kumar, P ;
Harlow, LA ;
Koch, AE .
CIRCULATION RESEARCH, 2003, 93 (04) :321-329
[7]  
[Anonymous], 2010, Cold Spring Harb. Perspect. Biol
[8]  
[Anonymous], J CLIN LAB ANAL
[9]  
[Anonymous], MOL CANC THER
[10]   An essential regulatory role for macrophage migration inhibitory factor in T-cell activation [J].
Bacher, M ;
Metz, CN ;
Calandra, T ;
Mayer, K ;
Chesney, J ;
Lohoff, M ;
Gemsa, D ;
Donnelly, T ;
Bucala, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7849-7854